Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment

    Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces
First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children

Sub-Saharan African Ministries of Health Invited to Submit Expression of
Interest to Participate in New Effort

Donation Program to be Part of Broader Initiative to Raise Awareness and

PR Newswire

CAPE TOWN, South Africa, Dec. 9, 2013

CAPE TOWN, South Africa, Dec. 9,2013 /PRNewswire/ --Janssen, the
pharmaceutical companies of Johnson & Johnson, today announced a
first-of-its-kind pediatric HIV treatment donation program to improve access
to the company's approved HIV medicines for children and adolescents failing
HIV treatment in sub-Saharan Africa. At a symposium entitled When Children
Need HIV Treatment Beyond First-Line: How Can We All Respond? at the 17^th
International Conference on AIDS and STIs in Africa (ICASA), Ministries of
Health (MOHs) in sub-Saharan Africa were invited to submit a formal Expression
of Interest to participate in the charitable pediatric HIV treatment donation

Through this program, Janssen will donate its HIV medicines PREZISTA^®
(darunavir) and INTELENCE^® (etravirine), including child-friendly
formulations, free of charge to eligible countries with the clinical capacity
and willingness to address second- and third-line pediatric HIV treatment.
Each child enrolled will receive Janssen's donated HIV medicines as needed
until they turn 19 at which point they will be transitioned into the adult
national HIV program or other designated by the national HIV program for
continued treatment.

The donation program is intended to be a first step in a broader collaborative
effort to build awareness, incite action, and advance learning around second-
and third-line pediatric HIV treatment in sub-Saharan Africa. Janssen is
working with the Elizabeth Glaser Pediatric AIDS Foundation, the Partnership
for Supply Chain Management (PFSCM), and MAP International to fully maximize
the impact and reach of this initiative.

"The donation program is part of our longstanding commitment to help people
living with HIV and enhance access to our medicines for those in need. Only a
third of the 3 million children living with HIV are receiving medicines today,
and of those children receiving treatment, a small but growing number are
experiencing HIV treatment failures and are in need of new treatment options,"
said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and
Worldwide Chairman, Janssen. "We hope this innovative donation program is the
first step in sparking further collaborative action across sub-Saharan Africa
for children who are experiencing HIV treatment failure. Our vision is that
these children receive the HIV treatment and care they need to stay healthy
and grow to become healthy, productive young adults."

Treatment of pediatric HIV remains significantly neglected in sub-Saharan
Africa. Responding to the challenge of HIV treatment-experienced children
requires a comprehensive effort to help guide countries in the provision of
necessary and appropriate care for this neglected population. This includes
improving understanding of the problem, expanding national treatment
guidelines beyond first-line, increasing healthcare capacity for pediatric HIV
treatment and monitoring, and ensuring that availability of co-administered
HIV medicines remains a priority.

The submission period for the Expression of Interest by country MOHs to
participate in the drug donation initiative will run from January 15, 2014
until February 14, 2014. An independent, third-party review committee of
international experts in pediatric HIV will review all applications to
determine country eligibility to receive the donation. Country approvals will
be announced in March 2014. Countries interested in more information or
submitting an Expression of Interest should visit:

About Janssen, the Pharmaceutical Companies of Johnson & Johnson
At Janssen, we are dedicated to addressing and solving the most important
unmet medical needs of our time, including in oncology (e.g., multiple myeloma
and prostate cancer), immunology (e.g., rheumatoid arthritis, IBD and
psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious
disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and
metabolic diseases (e.g., diabetes).

Driven by our commitment to patients, we develop sustainable, integrated
healthcare solutions by working side-by-side with healthcare stakeholders,
based on partnerships of trust and transparency. To learn more, visit

About Johnson & Johnson
Caring for the world, one person at a time…inspires and unites the people of
Johnson & Johnson. We embrace research and science – bringing innovative
ideas, products and services to advance the health and well-being of people.
Our approximately 128,700 employees at more than 275 Johnson & Johnson
operating companies work with partners in healthcare to touch the lives of
over a billion people every day throughout the world.

(This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of any of the Janssen
Pharmaceutical Companies or Johnson & Johnson. Risks and uncertainties
include, but are not limited to, general industry conditions and competition;
economic factors, such as interest rate and currency exchange rate
fluctuations; technological advances, new products and patents attained by
competitors; challenges inherent in new product development, including
obtaining regulatory approvals; challenges to patents; impact of business
combinations; changes in behavior and spending patterns or financial distress
of purchasers of health care products and services; changes to governmental
laws and regulations and domestic and foreign health care reforms; trends
toward health care cost containment; and increased scrutiny of the health care
industry by government agencies. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of Johnson &
Johnson's Annual Report on Form 10-K for the fiscal year ended December 30,
2012. Copies of this Form 10-K, as well as subsequent filings, are available
online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None
of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to
update any forward-looking statements as a result of new information or future
events or developments.)

SOURCE Janssen

Website: http://www.janssen.com
Contact: Karen Manson, kmanson@its.jnj.com, +44 (7717) 781 905
Press spacebar to pause and continue. Press esc to stop.